Immutep

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

biotech lab

Biotech

News

Health Care

Movers

Trading Ideas

General

IMMP

Immutep&#39;s efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels.

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

Display,Of,Stock,Market,Quotes

Pre-Market Outlook

Markets

CSTL

EVER

GPUS

ICHR

PLTR

RCUS

VRTX

Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

biotech shutter

Immutep&#39;s INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy.

Immutep&#39;s Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Immutep Limited - American Depositary Shares

Immutep Ltd

Press Releases

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Immutep Quarterly Activities Report Q2 FY25

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

First Patient Dosed in Immutep's TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep to Participate in Upcoming Investor Conferences

Immutep Quarterly Activities Report Q3 FY25

Immutep's Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

Immutep's Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Annexon

Candel Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Cardiff Oncology

Citius Oncology

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Design Therapeutics

Foghorn Therapeutics

Inhibrx Biosciences

Inozyme Pharma

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Monopar Therapeutics

Nanobiotix

Neurogene

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Tevogen Bio Holdings

Verastem

Y-mAbs Therapeutics

Baird

Capital One

Maxim Group

Comments

Immutep

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell